Role of additional medicine on ureteric stone expulsio
- Conditions
- Health Condition 1: N201- Calculus of ureter
- Registration Number
- CTRI/2022/12/048094
- Lead Sponsor
- Dr Arka Banerjee
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Subjects attending surgery OPD with diagnosis of ureteric stone
2.Subjects of either sex aged between 18-60 years.
3.Female subjects of reproductive age group willing to practice a medically accepted means of contraception.
4.Subjects willing to provide written informed consent for this study.
1.Ureteric stone measured > 10 millimeter in size
2.Patients with fever, high-grade hydronephrosis, acute kidney failure, UTI
3.Patients with history of urinary surgery or endoscopic treatment
4.Patients with Pregnancy, breastfeeding, Diabetes, Chronic kidney disease, peptic ulcer, hypotension, liver failure, Benign Prostate Hyperplasia, Hypertension,
5.Concomitant treatment with alpha-blocker drugs, betablockers, calcium channel blockers or nitrates
6.Declared hypersensitivity to Tamsulosin or corticosteroids
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the efficacy of low dose Deflazacort and Tamsulosin versus Tamsulosin alone in ureteric stone expulsionTimepoint: . Rate of stone expulsion of stone from ureter in 4 week follow up time
- Secondary Outcome Measures
Name Time Method To assess symptomatic improvement with low dose Deflazacort when added to Tamsulosin <br/ ><br>To Find out safety and tolerability of study drugs <br/ ><br>Timepoint: at day 14 after starting treatment and at day 28 after starting treatment